113. Muscular dystrophy Clinical trials / Disease details
Clinical trials : 646 / Drugs : 471 - (DrugBank : 105) / Drug target genes : 59 - Drug target pathways : 170
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2010-024659-10-DK (EUCTR) | 03/08/2011 | 21/06/2011 | Can certain muscle wasting diseases be improved with sildenafil? | Can stimulation of the nNOS system in muscle disease with nNOS insufficiency improve heart and skeletal muscle function and cognition? | Muscular dystrophy with nNOS insufficiency MedDRA version: 14.0;Level: LLT;Classification code 10028301;Term: Muscle disorder NOS;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] | Trade Name: Revatio Product Name: Sildenafil Product Code: EMEA/H/C/000638 | Rigshospitalet | NULL | Not Recruiting | Female: no Male: yes | Denmark | ||||
| 2 | NCT01168908 (ClinicalTrials.gov) | September 2010 | 22/7/2010 | Revatio for Heart Disease in Duchenne Muscular Dystrophy and Becker Muscular Dystrophy | Phase 2 Clinical Trial of Sildenafil for Cardiac Dysfunction in Duchenne Muscular Dystrophy and Becker Muscular Dystrophy | Duchenne Muscular Dystrophy;Becker Muscular Dystrophy | Drug: Sildenafil | Hugo W. Moser Research Institute at Kennedy Krieger, Inc. | Johns Hopkins University | Terminated | 18 Years | 50 Years | Male | 20 | Phase 2 | United States |